Flexion CEO: Setting Zilretta up to succeed with a history lesson

Locally acting therapies are like a religion to Flexion Therapeutics (NSDQ:FLXN) co-founder & CEO Dr. Mike Clayman, who spent decades at Eli Lilly (NYSE:LLY) with the company’s co-founder, Dr. Neil Bodick, watching promising compounds fail in late-stage trials on the heels of unanticipated safety results.

“That’s part of the reason, not the whole reason but part of the reason, why the industry only has a 60% success rate in Phase III, because you can’t predict what safety’s going to look like if you’re giving a systemically-administered product that has the potential for off-target effects,” Clayman told Drug Delivery Business News.

After testing and evaluating a number of in-licensed products, Flexion began with a promising candidate that they developed internally – an extended-release formulation of triamcinolone acetonide designed to help patients with osteoarthritis manage pain.

Get the full story at our sister site, Drug Delivery Business News.

The post Flexion CEO: Setting Zilretta up to succeed with a history lesson appeared first on MassDevice.

from MassDevice http://ift.tt/2ANV10k